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Abstract: Hypertension (HTN) affects about 1 billion people worldwide and the lack of a single
identifiable cause complicates its treatment. Blood pressure (BP) levels are influenced by environmental
factors, but there is a strong genetic component. Linkage analysis has identified several genes
involved in Mendelian forms of HTN and the associated pathophysiological mechanisms have been
unravelled, leading to targeted therapies. The majority of these syndromes are due to gain-of-function
or loss-of-functions mutations, resulting in an alteration of mineralocorticoid, glucocorticoid,
or sympathetic pathways. The diagnosis of monogenic forms of HTN has limited practical implications
on the population and a systematic genetic screening is not justifiable. Genome-wide linkage and
association studies (GWAS) have identified single nucleotide polymorphisms (SNPs), which influence
BP. Forty-three variants have been described with each SNP affecting systolic and diastolic BP by
1.0 and 0.5 mmHg, respectively. Taken together Mendelian inheritance and all GWAS-identified
HTN-associated variants explain 2–3% of BP variance. Epigenetic modifications, such as DNA
methylation, histone modification and non-coding RNAs, have become increasingly recognized as
important players in BP regulation and may justify a further part of missing heritability. In this review,
we will discuss how genetics and genomics may assist clinicians in managing patients with HTN.
Keywords: monogenic hypertension; genomics; genome-wide association studies; epigenetics;
pharmacogenomics
1. Introduction
Hypertension (HTN) is the most frequent modifiable risk factor for cardiovascular disease that
affects about 1 billion people worldwide [1,2]. Notwithstanding the major advances in understanding
the pathophysiology of HTN and the introduction of new treatment options, HTN remains a major
public health problem with a high socio-economic and health burden. Essential HTN is a multifactorial
disease and the lack of a single identifiable cause complicates the treatment of this condition.
Blood pressure (BP) levels are affected by modifiable factors such as salt, alcohol consumption,
obesity, physical activity and chronic stress. However, twin and family studies have demonstrated that
30–50% of the individual risk comes from genetic factors [3,4] and a family history of HTN increases
the risk of developing HTN by four times [5,6]. Over the last few decades a wealth of studies was
designed to understand the genetic basis of HTN and the associated molecular alterations. Three
different approaches have been used.
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The identification of genes involved in Mendelian forms of HTN by linkage analysis and next
generation sequencing, with description of rare variants with a major impact on BP levels. This approach
may identify the pathophysiological mechanism of a specific disorder and lead to a targeted therapy [7,8].
An approach based on families, twins and adopted children, or population studies using genome-wide
linkage and association studies (GWAS). The latter can identify single nucleotide polymorphisms (SNPs),
which influence the risk of developing high BP [8]. GWAS has also been applied to pharmacogenomic
studies to identify genetic variants that regulate pharmacokinetics and pharmacodynamics of
anti-hypertensive drugs [9].
More recently the study of epigenetic modifications has aroused growing interest; DNA
methylation, histone modification and non-coding RNAs have become recognized as important
players in several pathophysiological processes, including BP regulation [10].
Genetics is the study of the basis of heredity: how phenotypic features are transmitted from
one generation to the next and how a specific gene causes a particular disease, whereas genomics
is the study of the entire genome. In this review we discuss how genetics and genomics may assist
clinicians in managing patients with HTN. For this purpose, Pubmed database, Medline, Cochrane
Library and Biomed Central were searched for articles related to the key words “hypertension”
(combined with “genetics”, “genomics”, “pharmacogenomics” and “epigenetics”) and “monogenic
hypertension”. We selected the most relevant manuscripts pertinent to our review design, which
comprised monogenic forms of hypertension, large-scale genome-wide associations studies, epigenetic
modifications in hypertensive patients and pharmacogenomics.
2. Monogenic Forms of Hypertension
Over the last century, an increasing number of syndromes associated with high BP that are caused
by single rare gene mutations have been identified [11].
The discovery of genes responsible for monogenic forms of HTN identified the kidney and adrenal
glands as important players in the regulation of BP levels [12]. The majority of these syndromes are
due to gain-of-function or loss-of-function mutations, which result in an alteration of mineralocorticoid,
glucocorticoid, or sympathetic pathways (see Table 1).
Among the syndromes that affect the mineralocorticoid pathway, familial hyperaldosteronism is
the most frequent. Glucocorticoid-Remediable Aldosteronism (GRA), or familial hyperaldosteronism
type 1 (FH-1) results from an unequal crossing over between CYP11B1 (encoding for 11 β-hydroxylase)
and CYP11B2 (encoding for aldosterone synthase), leading to ACTH-dependent aldosterone secretion,
HTN, hypokalemia, low renin and high aldosterone levels. Low-dose glucocorticoids suppress
aldosterone production and normalize BP and potassium levels [13].
For familial hyperaldosteronism type 2 (FH-2) the causative gene has not yet been identified.
FH-2 is indistinguishable from sporadic primary aldosteronism (PA) except for the presence of more
members affected by PA within the same family. The diagnosis of this condition is made after exclusion
of other familial forms of PA [14].
Familial hyperaldosteronism type 3 (FH-3) is caused by mutations in KCNJ5, which encodes
the inwardly rectifying potassium channel Kir3.4. Described mutations are located near or within
the selectivity filter and are responsible for loss of ion selectivity, resulting in Na+ entry, membrane
cell depolarization, opening of voltage-dependent calcium channels, increase in calcium intracellular
concentration and aldosterone production [15]. Patients display severe hypokalemia, difficult-to-treat
HTN and bilateral adrenal hyperplasia. Bilateral adrenalectomy is necessary in most cases.
Recently, a fourth type of familial hyperaldosteronism (FH-4) has been described [16]. FH-4 is
caused by a germline gain-of-function mutation of CACNA1H, encoding for a T-type calcium channel.
CACNA1H constitutive activation leads to calcium entry and increased aldosterone production [17].
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Table 1. Hypertension (HTN)-related monogenic syndromes.
Monogenic Syndrome Inheritance Gene Locus Phenotype Therapeutic Indications
Pheochromocytomas/Paragangliomas Autosomal dominant
SDHA
SDHB
SDHC
SDHD
SDHAF2
TMEM127
MAX
5p15.3
1p36.13
1q23.3
11q23.1
11q12.2
2q11.2
14q23.3
Paragangliomas or pheochromocytomas. Surgery/α adrenergic blockers
von Hippel–Lindau syndrome Autosomal dominant VHL 3p25.3
Retinal, cerebellar and spinal
hemangioblastoma, renal cell carcinoma,
pheochromocytomas, pancreatic tumours.
Surgery/α adrenergic blockers
(for pheochromocytoma)
Multiple endocrine neoplasia, type 2A Autosomal dominant RET 10q11.2 Medullary thyroid carcinoma, parathyroidadenomas, pheochromocytoma.
Surgery/α adrenergic blockers
(for pheochromocytoma)
Neurofibromatosis type 1 Autosomal dominant NF1 17q11.2 Skin pigmentation, skin neurofibromas andbrain tumours. Pheochromocytoma.
Surgery/α adrenergic blockers
(for pheochromocytoma)
GRA–familial hyperaldosteronism type 1 Autosomal dominant CYP11B1CYP11B2 8q24.3 Familial form of PA Glucocorticoids
Familial hyperaldosteronism type 2 Autosomal dominant N.A. 7p22.3-7p22.1 Familial form of PA
Mineralocorticoid receptor
antagonist/unilateral adrenalectomy
(for APA)
Familial hyperaldosteronism type 3 Autosomal dominant KCNJ5 8q24.3 Severe form of PA with bilateral adrenalhyperplasia
Bilateral adrenalectomy in
drug-resistant patients
Familial hyperaldosteronism type 4 Autosomal dominant CACNA1H 16p13.3 Familial form of PA Mineralocorticoid receptorantagonist
PASNA syndrome N.A. CACNA1D 3p21.3
PA and complex neurological disorders
(seizures and functional neurological
abnormalities, resembling cerebral palsy).
N.A.
Sporadic APA N.A.
KCNJ5
ATP1A1
ATP2B3
CACNA1D
11q24.3
1p31.1
Xq28
3p21.3
Sporadic forms of PA. Adrenalectomy
Pseudohypoaldosteronism, type 2
(Gordon’s syndrome)
Autosomal dominant
(*dominant/recessive)
WNK1
WNK4
CUL3
KLHL3 *
12p12.3
17q21.2
2q36.2
5q31.2
HyperK+ hyperCl− metabolic acidosis. Low
PRA and low-normal AC. Thiazide diuretics
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Table 1. Cont.
Monogenic Syndrome Inheritance Gene Locus Phenotype Therapeutic Indications
Apparent mineralocorticoid excess
(AME) Syndrome Autosomal recessive HSD11B2 16q22.1
Hypokalemia. Low PRA and AC. Increased
cortisol/cortisone ratio.
Mineralocorticoid receptor
antagonist
Liddle’s syndrome Autosomal dominant SCNN1B,SCNN1G 16p12.2
ENaC constitutive activation. Hypokalemia.
Low PRA and AC.
ENaC blockers
(amiloride, triamterene)
11β-hydroxylase deficiency Autosomal recessive CYP11B1 8q24.3 Virilisation, short stature. Low PRA and AC.HypoK+ alkalosis.
Glucocorticoids to inhibit
ACTH-driven adrenal hyperpasia
17α-hydroxylase deficiency Autosomal recessive CYP17A1 10q24.3 HypoK
+ alkalosis. Absent sexual maturation.
Androgen deficiency.
Glucocorticoids to inhibit
ACTH-driven adrenal hyperpasia
Hypertension with brachydactyly Type E Autosomal dominant PDE3A 12p12.312p12.1
Brachydactyly, short phalanges and
metacarpals. N.A.
Hypertension exacerbated by pregnancy Autosomal dominant NR3C2 4q31.23 Early onset hypertension exacerbated duringpregnancy. N.A.
GRA, glucocorticoid remediable aldosteronism. PA, primary aldosteronism. N.A., not available. PASNA, primary aldosteronism, seizures and neurologic abnormalities. APA, aldosterone
producing adenoma. HyperK+, hyperkalemic. HyperCl−, hyperchloraemic. PRA, plasma renin activity. AC, aldosterone concentration. HypoK+, hypokalemic. ENaC, epithelial sodium
channel. Modified from Padmanabhan et al. [7].
Int. J. Mol. Sci. 2017, 18, 1131 5 of 17
Of note, somatic mutations in genes encoding ion pumps and channels (KCNJ5, ATP1A1,
ATP2B3, CACNA1D) in adrenal cells have been identified in more than 50% of patients with sporadic
APA [18,19]. Germline mutations in CACNA1D have been described in two patients with unexplained
PA and complex neurological disorders (seizures and functional neurological abnormalities, resembling
cerebral palsy) [20]. This syndrome was called PASNA (Primary Aldosteronism, Seizures and Neurologic
Abnormalities). Patients with PASNA are not able to transmit the mutation to their offspring because of
the severe neurological impairment.
Another Mendelian form of low-renin HTN is the Apparent Mineralocorticoid Excess (AME)
syndrome. Cortisol has a strong agonist activity on mineralocorticoid receptor (MR) and is present in a
100× higher concentration in bloodstream. HSD11B2 (type 2, 11β-hydroxysteroid dehydrogenase),
converting cortisol in cortisone, prevents its binding to MR. The loss-of-function mutation of HSD11B2
leads to cortisol-dependent activation of the MR resulting in sodium retention, hypokalemia, metabolic
alkalosis, suppressed renin and aldosterone levels and increased cortisol/cortisone ratio [21,22].
An acquired deficiency of this enzyme is determined by excessive liquorice intake (glycyrrihizic acid
from liquorice inhibit HSD11B2).
Gordon’s syndrome, also known as type 2 pseudo-hypoaldosteronism or familial hyperkaliemic
hypertension is characterized by HTN, hyperkalemia and hyperchloraemic metabolic acidosis [23]
(see Figure 1). The diagnosis is mainly clinical with subsequent identification of the causal mutation,
that however, is not obtained in all cases, indicating that as yet unidentified genes are associated
with this condition [24]. To date, mutations of 4 genes have been described: mutations in WNK1
and WNK4 kinases [25], and more recently KLHL3 and CUL3 mutations [26]. The net effect
of gain-of-function mutations in WNK1 and loss-of-function mutations in WNK4, KLHL3 and
CUL3 is the excessive activation of sodium-chloride co-transporter (NCC) and epithelial sodium
channel (ENaC) and the inhibition of the potassium channel ROMK, with increased reabsorption
of sodium and reduced excretion of potassium [27]. The identification of molecular mechanisms
underlying the pathology allows a targeted therapy with thiazide diuretics, which inhibit NCC, revert
hyperkalaemia and normalize BP. Recently, GILZ (glucocorticoid induced leucine zipper protein) has
been demonstrated to modulate renal potassium homeostasis; GILZ-knockout mice had hyperkalemia
due to hyperstimulation of NCC, representing a reliable model of Gordon syndrome (even if mice had
normal BP values) [28].
Liddle’s syndrome leads to hypokalemia, suppressed renin and aldosterone levels and a severe
increase of BP, often resistant to anti-hypertensive agents, during childhood (see Figure 1). The disease
is determined by gain-of-function mutations in the β- or γ- subunit of ENaC, with a consequent
aldosterone-independent sodium retention. The mutations result in the inability to remove ENaC from
the cell surface [29–31]. The treatment with ENaC inhibitors, such as amiloride, is highly effective in
lowering BP and normalizing potassium levels.
Congenital adrenal hyperplasia (CAH) syndromes are a group of diseases caused by mutations
in enzymes involved in glucocorticoid synthesis. In particular mutations in CYP11B1 and CYP17A1
(encoding for 11β-hydroxylase and 17α-hydroxylase, respectively) are associated with early onset HTN
and hypokalemia. In these patients, ACTH is increased due to the absence of cortisol negative feedback
resulting in adrenal hyperplasia and accumulation of cortisol precursors with mineralocorticoid activity
(such as 11-deoxycorticosterone, DOC), which leads to HTN and hypokalemic alkalosis. Virilisation
in affected females due to excessive androgen synthesis is also present in patients with CYP11B1
deficiency [32] and pseudo-hermaphroditism in affected males with CYP17A1 deficiency due to a
deficit of androgen synthesis [33]. A CYP11B1 deficiency phenotype can also result from recombination
between CYP11B2 and CYP11B1 genes thereby producing a hybrid CYP11B2/B1 gene [34].
Hypertension with brachydactyly Type E is associated with a missense mutation of the PDE3A
gene, encoding for phosphodiesterase 3A. This syndrome is characterized by severe salt-independent
but age-dependent HTN and short phalanges and metacarpals [35,36]. The mutation increases protein
kinase A-mediated PDE3A phosphorylation in vitro, which results in enhanced cell proliferation
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and contraction in mesenchymal stem cell-derived vascular smooth muscle cells. The mechanism
underlying HTN development is not fully elucidated, but authors suggest that these alterations may
produce vascular hypertrophy and increase of peripheral vascular resistances [37].
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Nedd4 and Nedd4-2 regulate membrane endocytosis and exocytosis, through cAMP-dependent 
pathways and aldosterone/serum and glucocorticoid-regulated kinase (SGK). Panel B—ENaC gain-
of-function mutations determine resistance to Nedd-mediated ubiquitination with ENaC over-
expression. ENaC inhibitors (such as amiloride) block ENaC and normalize BP. Panel C—Na+-Cl− co-
transporter (NCC), potassium channel (ROMK) and ENaC are responsible for Na+ and K+ homeostasis 
in DCT. Different intracellular factors regulate the activity of these transporters: WNK1 and WNK4 
(kinases which inhibit NCC and ROMK), KLHL3 and CUL3 (ubiquitin ligases which mediate WNK 
kinases degradation). Panel D—The net effect of gain-of-functions mutations in WNK1 and loss-of-
function mutations in WNK4, KLHL3 and CUL3 is the excessive activation of NCC and ENaC and 
the inhibition of ROMK, with increased reabsorption of sodium and reduced excretion of potassium. 
Thiazide diuretics block NCC and normalize BP. Arrows indicate up-regulation whereas lines ending 
in closed circles indicate down-regulation. Fine lines indicate established pathways, whereas dotted 
lines indicate pathways observed in in vitro models. The effects of mutations are indicated in red. 
Modified from Pathare 2013 [27] and Snyder 2002 [29]. 
A form of HTN that is exacerbated by pregnancy is caused by a Ser810Leu mutation in the MR. 
The mutation results in constitutive activation of the receptor and is proposed to impair MR 
specificity such that some steroid hormone antagonists (such as progesterone and cortisone) act as 
agonists to the mutated receptor [38,39]. Affected women display severe HTN during pregnancy, 
with elevated progesterone levels; delivery improves HTN but there is no specific treatment for men 
and non-pregnant women. Spironolactone increases BP by activating the MR [38,39]. 
Among syndromes that affect sympathetic pathways about 30% of pheochromocytoma and 
paragangliomas are associated to germline mutations. The described mutations affect the equilibrium 
between oncogenes and onco-suppressor genes. In particular, mutations of VHL, SDHA, SDHB, 
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Figure 1. Gordon and Liddle syndromes. Panel A—Epithelial Na+ Channel (ENaC) is expressed in the
distal convoluted tubule (DCT) at the apical membrane, where it allows Na+ in the lumen to enter the
cell. At the baso-lateral membrane, Na+ is pumped outwards by Na+-K+ ATPase. ENaC membrane
expression is regulated through membrane trafficking. Aldosterone (Aldo), vasopressin (ADH), Nedd4
and Nedd4-2 regulate membrane endocytosis and exocytosis, through cAMP-dependent pathways
and aldosterone/serum and glucocorticoid-regulated kinase (SGK). Panel B—ENaC gain-of-function
mutations determine resistance to Nedd-mediated ubiquitination with ENaC over-expression. ENaC
inhibitors (such as amiloride) block ENaC and normalize BP. Panel C—Na+-Cl− co-transporter (NCC),
potassium channel (ROMK) and ENaC are responsible for Na+ and K+ homeostasis in DCT. Different
intracellular factors regulate the activity of these transporters: WNK1 and WNK4 (kinases which inhibit
NCC and ROMK), KLHL3 and CUL3 (ubiquitin ligases which mediate WNK kinases degradation).
Panel D—The net effect of gain-of-functions mutations in WNK1 and loss-of-function mutations in
WNK4, KLHL3 and CUL3 is the excessive activation of NCC and ENaC and the inhibition of ROMK,
with increased reabsorption of sodium and reduced excretion of potassium. Thiazide diuretics block
NCC and normalize BP. Arrows indicate up-regulation whereas lines ending in closed circles indicate
down-regulation. Fine lines indicate established pathways, whereas dotted lines indicate pathways
observed in in vitro models. The effects of mutations are indicated in red. Modified from Pathare
2013 [27] and Snyder 2002 [29].
A form of HTN that is exacerbated by pregnancy is caused by a Ser810Leu mutation in the
MR. The mutation results in constitutive activation of the receptor and is proposed to impair MR
specificity such that some steroid hormone antagonists (such as progesterone and cortisone) act as
agonists to the mutated receptor [38,39]. Affected women display severe HTN during pregnancy, with
elevated progesterone levels; delivery improves HTN but there is no specific treatment for men and
non-pregnant women. Spironolactone increases BP by activating the MR [38,39].
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Among syndromes that affect sympathetic pathways about 30% of pheochromocytoma and
paragangliomas are associated to germline mutations. The described mutations affect the equilibrium
between oncogenes and onco-suppressor genes. In particular, mutations of VHL, SDHA, SDHB, SDHC,
SDHD and SDHAF2 alter the pathway related to hypoxia cellular responses mediated by hypoxia
inducible factors, whereas mutations of RET and NF1 are associated to a constitutive activation
of RAS/RAF/MEK and PI3KT/AKT/mTOR signalling [40]. Patients harbouring VHL, RET or
NF1 mutations show syndromic diseases, such as von Hippel-Lindau syndrome (retinal, cerebellar
and spinal hemangioblastoma, renal cell carcinoma, pancreatic tumours and pheochromocytoma),
type IIA multiple endocrine neoplasia (medullary thyroid carcinoma, parathyroid adenomas and
pheochromocytoma) and type 1 neurofibromatosis (skin pigmentation, neurofibromas, brain tumours,
and pheochromocytoma) [41]. Because of the impact on the diagnosis, prognosis and the possibility
of early detection of the disease in relatives, the systematic targeted genetic screening should be
considered in clinical practice for patients with a diagnosis of pheochromocytoma or paragangliomas.
These are some examples in which the description of a rare genetic mutation has enabled
the understanding of disease pathogenesis and in some cases the identification of a molecular
pharmacologically-targetable pathway. However the diagnosis of these syndromes has limited practical
implications on the population, even in cases of a systematic genetic screening of all young hypertensives,
which is not justifiable unless in the presence of features that suggest syndromic diseases.
3. Large-Scale Genome-Wide Associations Studies
The study of monogenic forms of HTN improved the knowledge of physiological mechanisms
regulating BP. Nevertheless, Mendelian disorders are rare and do not explain the genetic component
in patients with essential HTN. Indeed, most human genome variability is determined by SNPs. SNPs
are structural variations of a single nucleotide, which occur in a specific position of the genome [42].
The large-scale identification of these polymorphisms has been made possible by linkage and
association mapping [43]. Genetic linkage is the tendency of close alleles on a chromosome to be
inherited together. Linkage analysis is based on this trend and identifies genetic regions of interest
by mapping the genome of families with rare syndromes. This method has been highly successful
for the identification of monogenic disorders, but it has also been applied in patients with essential
HTN. The BRIGHT study supported the linkage of a locus on chromosome 5q13 with essential
HTN susceptibility [44], whereas two other studies demonstrated a linkage with multiple loci on
chromosome 1q [45,46].
Association mapping is a technique of mapping expression quantitative trait loci (eQTL), which
link phenotypes and genotypes of a population, taking advantage of linkage disequilibrium [47].
Association mapping studies are better suited for complex genetic traits such as HTN but require a
higher number of patients compared to linkage analysis and the extensive knowledge of all SNPs
within the genome of the organism of interest [48].
Recent technological advances have opened the door to genome-wide association studies (GWAS).
GWAS methodology is based on the determination of the statistical association between each SNP and
the pressure phenotype through a linear regression analysis [12]. Pressure phenotype is influenced
by environmental factors, including anti-hypertensive medications. In GWAS, BP levels are adjusted
for age, sex and BMI; subsequently by convention, +15/+10 mmHg are added respectively to systolic
blood pressure (SBP) and to diastolic blood pressure (DBP) in the presence of pharmacological therapy
with at least one anti-hypertensive drug [49].
The two (rarely three or more) alleles for each SNP have different prevalence in the population;
the least frequent allele is defined as the minor allele. The minor allele frequency (MAF) is inversely
proportional to the total number of SNPs in the population [50].
Therefore, the statistical power of GWAS is proportional to sample size, MAF and each SNP-effect
on SBP/DBP and inversely proportional to the number of independent tests performed (which is equal
to the number of SNPs analysed). Therefore, SNPs with an allele frequency less than 5% have a too low
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predictive power, whereas more frequent variants may represent attractive targets for multifactorial
diseases because of the expected stronger impact [51].
The first attempt to identify variants associated with HTN by GWAS was performed in 2007 on
2000 patients with HTN, but failed to identify any association probably because of the small sample
size (GWAS by the Wellcome Trust Case Control Consortium) [52]. Later studies with larger sample
sizes were subsequently performed: in 2011 the International Consortium for Blood Pressure GWAS
(ICBP) completed the analysis of over 200,000 subjects [49], identifying 29 SNPs associated with HTN.
Using candidate gene focused arrays, the described variants increased to 43 [53] but the effect size for
each SNP was demonstrated to be about 1 mmHg for SBP and 0.5 mmHg for DBP (see Table 2) [12].
A risk score combining the effects of each variation was built with all the identified SNPs: the resulting
score proved to be predictive of HTN if applied to different populations, but explained only a small
part of the phenotypic variance among patients. Furthermore, it was also associated with the risk of
stroke, coronary artery disease and left ventricular hypertrophy, but not with renal failure, indicating
that the relationship between HTN and kidney function is more complex than expected [49].
Finally, only a minority of all the 43 described variants were near a gene known to be associated
with BP levels [12]. The remaining SNPs were located in regions of the genome which were not thought
to be related to HTN and were thus proposed as future sequencing targets to identify new biological
pathways associated with pathophysiological alterations and potentially new therapeutic targets.
Taken together all GWAS-identified HTN-associated variants only explain 2–3% of BP variance [8,49],
whereas the expected heritability varied between 30% and 50% [3,4]. However, studying a specific
cohort under a specific environment overestimates the expected heritability and it is also likely that
many more SNPs remain to be discovered [7].
Table 2. Genetic variants associated with hypertension.
SNPs Nearest Gene(s) Position Encoded Protein Function
rs880315 CASZ 1p36.22 Zinc finger transcription factor that acts as tumour suppressor.
rs4846049 MTHFR(3′)-NPPB 1p36.22
MTHFR catalyse the conversion of 5,10-MTH in 5-MTH and it is
involved in homocysteine metabolism.
NPPB encodes for the B natriuretic peptide.rs17367504 MTHFR(5
′)-NPPB
rs17030613 ST7L-CAPZA1 1p13.2 ST7L is a tumour suppressor factor.CAPZA1 regulates growth of actin filaments.
rs2932538 MOV10 1p13.2 A component of the RISC complex RNA helicase.
rs2004776 AGT 1q42.2 Pre-angiotensinogen.
rs16849225 FIGN-GRB14 2q24.3
FIGN regulates microtubules synthesis.
GRB4 is a growth factor receptor-binding protein, which interacts
with insulin receptors and insulin-like growth factors.
rs13082711 SLC4A7 3p24.1 Sodium bicarbonate co-transporter in neuronal cells, involved invisual and auditory transmission.
rs3774372 ULK4 3p22.1 Serine/Threonine kinase involved in neurite branching andelongation and neuronal migration.
rs319690 MAP4 3p21.31 Promotion of microtubule assembly.
rs419076 MECOM 3q26.2 Transcriptional regulator and oncoprotein involved in apoptosis,hematopoiesis, cell differentiation and proliferation.
rs1458038 FGF5 4q21.21 Fibroblast growth factor 5, involved in embryonic development, cellgrowth, morphogenesis, tissue repair, tumour growth and invasion.
rs13107325 SLC39A8 4q24 Mitochondrial cellular import of zinc, involved in inflammation.
rs6825911 ENPEP 4q25 Glutamyl aminopeptidase; associated with renal neoplasm.
rs13139571 GUCY1A3-1B3 4q32.1 Guanylate cyclase 1 soluble subunit α, involved in nitric oxidepathway transduction.
rs1173771 NPR3-C5orf23 5p13.3 Natriuretic peptide receptor 3, responsible for clearing natriureticpeptides through endocytosis of the receptor.
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Table 2. Cont.
SNPs Nearest Gene(s) Position Encoded Protein Function
rs11953630 EBF1 5q33.3 Early B-cell factor 1, associated with central obesity, B-lymphocytesdifferentiation and Hodgkin lymphoma.
rs1799945 HFE 6p22.2 Hemochromatosis protein; regulation of iron absorption.
rs805303 BAT2-BAT5 6p21.33
Genes cluster localized near genes for TNF α and β, involved in
inflammatory process and associated with insulin dependent
diabetes and rheumatoid arthritis.
rs17477177 PIK3CG 7q22.3 A catalytic subunit of PI3K, involved in the immune response.
rs3918226 NOS3 7q36.1 Endothelial nitric oxide synthase.
rs2898290 BLK-GATA4 8p23.1
BLK is a tyrosine kinase involved in cell proliferation and
differentiation. GATA4 is a zinc finger transcription factor involved
in embryogenesis and myocardial differentiation and function.
rs1799998 CYP11B2 8q24.3 Aldosterone synthase.
rs4373814 CACNB2(5′) 10p12.33 Member of a voltage-gated calcium channel superfamily, associated
with Brugada and Lambert-Eaton myasthenic syndrome.rs1813353 CACNB2(3′)
rs4590817 C10orf107 10q21.2 Chromosome 10 open reading frame 107. Unknown function.
rs932764 PLCE1 10q23.33 Phospholipase involved in Ras pathway, associated with early onsetnephrotic syndrome.
rs11191548 CYP17A1-NT5C2 10q24.32
CYP17A1 is the 17α hydroxylase, involved in the steroidogenic
pathway; mutated in congenital adrenal hyperplasia.
NT5C2 is a hydrolase involved in purine nucleotides metabolism.
rs1801253 ADRB1 10q25.3 Adrenoreceptor β1, which mediate physiological effects ofepinephrine and norepinephrine.
rs7129220 ADM 11p15.4
Pre-hormone cleaved in adrenomedullin and pro-adrenomedullin,
which act as vasodilator, hormone secretion regulators and
angiogenesis promoters.
rs381815 PLEKHA7 11p15.2 Pleckstrin homology domain containing A7 associated with breastcarcinomas and glaucoma.
rs633185 FLJ32810-TMEM133 11q22.1 FLJ32810 is a regulator of vascular tone.TMEM133 is a transmembrane protein; unknown function.
rs17249754 ATP2B1 12q21.33 Calcium ATPase with critical role in intracellular Ca2+ homeostasis
rs3184504 SH2B3 12q24.12 Signalling activities by growth factor and cytokine receptors;associated with celiac disease and insulin-dependent diabetes.
rs11066280 ALDH2 12q24.12 Mitochondrial aldehyde dehydrogenase 2, involved in the oxidativepathway of alcohol metabolism.
rs10850411 TBX5-TBX3 12q24.21 T-box protein family encoding for transcriptional factors regulatingheart and limbs developmental processes.
rs1378942 CYP1A1-ULK3 15q24.1
CYP1A1 is a mono-oxygenases involved in drug catabolism and
synthesis of cholesterol, steroid and other lipids.
ULK3 is a serine/threonine kinase; unknown function.
rs2521501 FURIN-FES 15q26.1
FURIN is a protease, involved in the catabolism of PTH, TGFβ1 and
other growth factors. FES is a tyrosine kinase, involved in
hematopoiesis and cytokine receptor signalling.
rs13333226 UMOD 16p12.3 Regulation of renal sodium handling. See text.
rs17608766 GOSR2 17q21.32 Trafficking membrane protein.
rs12940887 ZNF652 17q21.32 Zinc finger protein, associated with breast and prostate cancer.
rs1327235 JAG1 20p12.2 Hematopoiesis regulation through notch 1 signalling.
rs6015450 GNAS-EDN3 20q13.32
GNAS is a G-protein that activates adenylyl cyclase with a wide
variety of cellular responses. EDN3 encode for endothelin 3,
implicated also in neural crest-derived cell lineages differentiation.
The table reports the 43 SNPs associated with blood pressure and the nearest gene (when there were two flanking
genes, we reported both). Only a minority of the reported SNPs are near a gene known to be related to BP. Modified
from Ehret et al. [12].
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4. Epigenetic Modifications in Hypertensive Patients
Epigenetics includes all heritable changes in gene expression regulation, which do not involve
mutations in the DNA sequence [54]. Epigenetic modifications can be determined by many factors
such as environmental influences during foetal life and childhood, exposure to chemical agents, aging,
diet, medications and others [55]. Research in the field of epigenetic modifications provides insights on
how the regulation of BP levels cannot be explained just by Mendelian inheritance [10,56] and could
also justify a further part of the missing heritability, unexplained by GWAS. The processes that may
cause epigenetic modifications of DNA include methylation, post-translational histone modification
and mechanisms based on small non-coding RNAs [10] (see Table 3).
DNA methylation is the transfer of a methyl group from S-adenosyl-L-methionine to the
5′-position of a cytosine ring, to form 5-methyl-cytosine (5mC). This occurs in specific genomic
regions called CpGs islands, composed of a series of dinucleotides, guanine and cytosine. Of note, CpG
islands are often located in promoter regions [10]. DNA methylation down-regulates gene transcription
resulting in gene silencing [55]. In patients with HTN the total number of 5mC is decreased with
increasing HTN severity [57]. Furthermore, HSD11B2 gene promoter methylation is associated
with HTN onset [58], as well as hypomethylation of genes of the renin-angiotensin-aldosterone
(RAA) system or NKCC1 (Na-K-Cl co-transporter 1) gene respectively affect the response to ACE
(angiotensin-converting enzyme) inhibitors and diuretics [59,60].
Table 3. Epigenetic modifications in hypertension.
Epigenetic Modification Findings/Effectors Reference
DNA methylation
Amount of 5mC in DNA inversely proportional to
BP levels Smolarek et al. [57]
HSD11B2 promoter methylation associated with HTN
onset at young age Friso et al. [58]
RAA system gene hypomethylation associated with HTN
in offspring, BP regulation and ACE inhibitor response.
Goyal et al. [59]
Pei et al. [61]
Rivière et al. [62]
Hypomethylation of SIC2A2 associated with NKCC1
overexpression, Na+ reabsorption and HTN. Lee et al. [60]
Histones
acetylation/deacetylation
Acetylation/deacetylation of endothelial cells
nucleosomes regulate eNOS expression Fish et al. [63]
Nucleosomes modifications regulate ACE transcription Lee et al. [64]
Nucleosomes modifications regulate NKCC1 transcription
and sodium renal reabsorption Cho et al. [65]
WNK4 down-regulation determines histones acetylation
and NCC overexpression. Mu et al. [66]
Non coding RNA
miR-27a and -27b down-regulate ACE1 mRNA Goyal et al. [59]
miR-155 down-regulate AGTR1 mRNA Cheng et al. [67]
miR-181a and -663 down-regulate renin mRNA and are
under-expressed in HTN-patients Marquez et al. [68]
miR-425 down-regulate NNPA, leading to ANP
under-production and salt overload Arora et al. [69]
5mC, 5-methil-cytosine. BP, blood pressure. HSD11B2, hydroxysteroid 11-β dehydrogenase 2. HTN, hypertension.
RAA, renin-angiotensin-aldosterone system. ACE, angiotensin converting enzyme. NKCC1, Na-K-Cl co-transporter 1.
eNOS, endothelial nitric oxide synthase. NCC, NaCl co-transporter. miR, microRNA. AGTR1, angiotensin II type 1
receptor. ANP, Atrial natriuretic peptide. Modified from Wise et al. [10].
Histones package DNA into structural units called nucleosomes. Post-translational DNA
modifications include histone acetylation, or less frequently methylation and phosphorylation [70].
Histone acetylation promotes gene transcription, whereas deacetylation produces the opposite
effect [71]. Acetylation or deacetylation of eNOS (endothelial nitric oxide synthase), RAA system
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genes, NKCC1, NCC or WNK4 were demonstrated to affect vascular tone, renal hydro-electrolyte
homeostasis and therefore BP [63–66].
Finally, small non-coding RNAs are also implicated in epigenetic modifications. In particular
microRNAs (miRNA/miR) may down-regulate genes by binding the corresponding mRNA, resulting
in the degradation of the latter and repression of translation [72]. miRNA with a possible role in BP
regulation are listed in Table 3 [59,67,68,73].
Through these mechanisms the environment could influence genotype in each individual and
these findings complicate the field of HTN genetics and genomics, adding another factor able to modify
the phenotypic expression of patients with HTN [10].
5. Pharmacogenomics
Theoretically genomics can also be applied to predict drug response. The goal of pharmacogenomics
is to identify genetic variants associated with a better response to a pharmacological class over another,
in the attempt to administer “the right dose of the right drug to the right patient” [74]. In Table 4 we
report some significant studies published on how a patient's genotype can affect pharmaco-kinetics or
-dynamics of a given drug.
An example of this type of study is the SOPHIA study: 372 patients with HTN treated in monotherapy
with losartan were included in the analysis. Through a whole-genome approach, the authors identified
a significant association between 4 SNPs on CAMK1D gene and BP response. CAMK1D encodes for a
calcium-dependent kinase that modulates the transcription of factors NURR1, ARF1, ATF2 and CREB,
involved in aldosterone production in the adrenal zona glomerulosa [75].
Pharmacogenomics may also be applied to the identification of new therapeutic targets in patients
with HTN. GWAS on Milan hypertensive rats and humans revealed the ADD1 gene (encoding for
α-adducin), as an eQTL associated to a significant increase in BP [76,77]. Adducin is a cytoskeletal
protein consisting of two subunits: a α-subunit associated to either a β- or a γ-subunit. Mutated
α-adducin stimulates the Na+/K+ ATPase in tubular renal cells, increasing Na+ reabsorption. Ouabain,
a hormone released by hypothalamus and adrenal glands, is able to modulate Na+/K+ ATPase activity
and natriuresis. Rostafuroxin antagonizes ouabain and lowers BP. Plasma ouabain levels are directly
correlated with the number of copies of the mutated α-adducin gene [78]. The OASIS-HT [79] and the
PEARL (ongoing) randomized controlled trials investigated the BP response to rostafuroxin through a
pharmacogenomic approach.
Another example is uromodulin (UMOD) genes. In 2010, its minor allele was demonstrated to
be associated with a lower risk of HTN [80] and reduced urinary uromodulin excretion [80]. UMOD
encodes for a protein expressed in the kidney, exclusively in the thick ascending limb of the loop of
Henle [81]. UMOD knockout models in vivo had lower SBP and were resistant to salt-induced changes
of BP [82], whereas UMOD overexpression produced an increase in UMOD renal excretion and BP
levels [83]. Furthermore, furosemide significantly increased natriuresis and decreased BP in the latter
model compared to wild type controls [83]. These findings suggest that patients with increased urinary
UMOD excretion may have an enhanced response to loop diuretics and that the uromodulin pathway
may represent a new target for future drug development [81].
Although studies are promising with possible practical applications, these results should be
interpreted with caution because their reproducibility was poor, suggesting that the observed
associations may not be effective or that they are applicable only within specific sub-populations [84].
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Table 4. Main genetic associations with response to anti-hypertensive drugs.
Genetic Association Effect Reference
NEDD4L, PRKCA,
GNAS-EDN3, TET2,
CSMD1, HSD3B1
Enhanced response to thiazide diuretics
Dahlberg et al. [85]
Duarte et al. [86]
Chittani et al. [87]
Salvi et al. [88]
ADRB1 Enhanced response to metoprolol Ganesh et al. [89]
ADRB1 Enhanced response to carvedilol Mialet-Perez et al. [90]
ADRB1 Greater mortality in patients treated with verapamilthan with atenolol Karlsson et al. [91]
CYP2D6 Decrease in metoprolol clearance Rau et al. [92]
GRK4 Enhanced response to atenolol Bhatnagar et al. [93]
SIGLEC12, A1BG, F5 Higher risk of treatment-related adverse CVoutcomes in patients treated with CCB Hannila et al. [94]
CAMK1D Enhanced response to losartan Frau et al. [75]
ADD1 Enhanced response to rostafuroxin Staessen et al. [79]
The table describes the effects of SNPs in genes indicated in the first column. CV, cardiovascular. CCB, calcium
channel blockers. Modified from Cooper-DeHoff et al. [9].
6. Conclusions
Genetic and genomics studies have provided major insights into understanding the pathogenesis
of HTN. Identification of Mendelian syndromes allows an effective targeted therapy, however, they are
relatively rare diseases with limited economic-health implications. On the other hand, essential
HTN is very frequent but clinical applications of GWAS are undefined. The challenge lies in
moving from the identification of SNPs associated with hypertension to the description of new
pharmacologically-targetable causal molecular mechanisms. An example is the discovery of UMOD by
GWAS studies and the subsequent description of a new potentially targetable pathway. Considering
the complexity of BP regulation, only a minority of all pharmacologically targetable pathways are
known. It is possible that further technological innovations will provide tools able to unequivocally
define the genetic architecture of HTN and provide new therapeutic options for hypertensive patients.
A future perspective could be the definition of scores on HTN-related SNPs to predict which patients
will develop HTN and to which therapy they will respond better.
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